Foresite Labs is a company focused on healthcare innovation, providing an incubation platform that aims to dismantle barriers to innovation in the life sciences sector.

Foresite Labs

Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. 

Foresite Labs Values
Truth over progression: We follow the science, pursuing ideas that are grounded in data and abandoning them when not supported by the evidence.

Take good risks: Our culture values informed risk-taking: good decisions are celebrated even when they result in bad outcomes. Everyone feels safe to contribute ideas and to learn from failure.

Single accountable person: The project team lead is accountable for all decisions and for maintaining transparency and information flow within the team; we trust the project teams. The Review Committee unlocks capital and sets directions.

Simplicity and Focus: “Companies die from indigestion, not starvation” (Bill Hewlett) We will focus on a few ideas aggressively and minimize all other distractions. Everyone will have a few key goals that have measurable outcomes.

Respect and Community: Our employees are our greatest asset; everyone invests in creating an environment of collaboration and respect. We support their careers and career development whether they stay, go to a Labs company, or end up somewhere else.

Last week was quite a week! Congratulations to Martin Babler & the team at Alumis on their IPO. Alumis was incubated by Foresite Labs; the company is developing two Tyrosine Kinase 2 inhibitor product candidates for patients living with immune-mediated diseases who need alternatives to existing treatments. This achievement represents years of work from the therapeutics team at Foresite Capital and the incubation team at Foresite Labs. Congrats to all!

I have an open position on my team for an experienced statistical and translational geneticist with a desire to apply his/her skills to biotech incubation. Want to learn about new venture creation and work with a team experienced in generating insights that can be used to improve patient lives? Let’s talk!

Our CEO Vik Bajaj is at HLTH Europe and will be speaking at the Touch Stage at 12:20 PM CEST for the panel discussion “Square peg, square hole - Unleashing the potential of genomics and personalized therapies”. Join him and industry experts Jason C. Foster, Dana Mendenhall, Benjamin Zaniello, MD MPH w/ moderator Rabab Nasrallah, PhD to learn about the potential that new therapies will have on the healthcare system as we know it. 

More about HLTH Europe here: https://europe.hlth.com/

Great progress at our incubated company Alumis. Congrats to the team on this progress.

News today from Foresite Labs' company, Alumis, which uses a precision medicine approach in its aim to transform the lives of patients with immune-mediated diseases. #psoriasis

Former Foresite Labs Fellow and current associate Chase Kelley recently sat down with Scott McIsaac to discuss his experiences participating in the joint Foresite Capital & Foresite Labs Fellows program. Check it out at the link below. We are now accepting applications for our upcoming cohort: https://lnkd.in/gJuaCbPR

FORE

COM:FORESITELABS

Foresite Labs